labfolder GmbH, a electronic laboratory notebook (ELN, Electronic Lab Notebook) provider, and cubuslab GmbH, a provider of a manufacturer-independent platform for the digital integration of laboratory instruments, today announced their merger. The joint company will operate under the name L ... more
labfolder expands to North America
Collaboration with the German Accelerator Life Sciences
labfolder and the German Accelerator Life Sciences (GALS), an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi), today announced the initiation of an extensive collaboration supporting the company’s expansion into the North American markets. With thousands of users and a growing number of customers in the U.S. already, the newly established Cambridge office will accelerate those efforts and support customer relations.labfolder digital lab notebook software was developed to support research teams in managing their vast amounts of data, and being more productive in the lab. The company is one of the world's leading electronic lab notebook (ELN) platforms with a strong user base within life sciences, biotech and pharma.
“The Boston/ Cambridge biotech hub is an important market for the laboratory supply industry with hundreds of top-tier biotech and pharmaceutical companies, the top 4 NIH-funded hospitals in the U.S., and 122 colleges and universities. Academic research institutions as well as industrial R&D giants worldwide are looking towards Boston as one of the most innovative regions. For us it is not only a great opportunity, but also an honor being able to support research teams with our software, and helping them to focus on making groundbreaking discoveries.”, said Simon Bungers, Co-founder and CEO of labfolder.
“Since the first public release of our software in 2013, we have seen high user growth in the U.S. and just within the last year we have increased our customer-base within this market by 10-fold. Researchers everywhere are looking for a simple, easy-to-use solution to manage the vast amounts of data produced in a lab each year and store them in a safe and accessible way,” added Florian Hauer, Co-founder and COO of labfolder. “We are planning to aggressively expand our US customer base and our newly established U.S. office as well as our collaboration with the GALS team will help to deliver on these strategic plans.”
As of 2014, labfolder offers a standalone server solution next to the cloud version. Customers can also benefit from added support for managing extensive datasets, team management, and collaboration features, as well as a material database to manage inventory. Offering these features paved the way to the company’s success. labfolder customers include Germany’s most renowned research organization, the Max-Planck-Society as well as Europe’s large university hospital, the Charité Berlin, among others.
“labfolder won the trust of leading research institutions and companies in Germany,” says Christoph Lengauer, CEO of GALS. “I am convinced that the labfolder team will be able to leverage this success for partnering here in Cambridge and the U.S. in general.” GALS will provide strategic as well as operational support for labfolder and leverage its industry network to support the company’s further expansion into the U.S. market.
labfolder GmbH and the Max Planck Society announced a licensing agreement to provide up to 11,000 Max Planck scientists with labfolder's laboratory data management digital platform. This is the first time that a tool for digital laboratory data management is being provided across an entire ... more
- 1New Indication of a Link Between Alzheimer’s and Diabetes
- 2Click... Resistant bacteria caught in the act!
- 3Nanosafety research without animal experiments
- 4The relationship of proteins
- 5DKSH extends partnership with Bruker in China
- 6Detecting antibodies with glowing proteins, thread and a smartphone
- 7High-end Microscopy Refined
- 8Developing new techniques to improve atomic force microscopy
- 9RNA structures by the thousands
- 10Could the blood of COVID-19 patients be used to predict disease progression?